… COVID-19 patients. We attempted to verify the effectiveness and safety of tocilizumab therapy
in COVID-… a randomized, controlled, open-label multicenter trial among COVID-19 patients. …

… Patients with COVID-19 pneumonia can have increased … of patients with moderate-to-severe
COVID-19 pneumonia. … in patients with moderate-to-severe COVID-19 pneumonia. Further …

… sarilumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation.
Methods We conducted an open-label study of sarilumab in severe COVID-19 pneumonia (…

… We performed a randomised, open-label, controlled trial involving hospitalised patients
with confirmed COVID-19 pneumonia needing oxygen therapy. Patients were randomly …

… from a single center open label phase II parallel arm randomised control trial done in a
single center in Eastern India, done on patients suffering from severe COVID-19 disease with …

… by the worsening clinical status of patients with severe COVID-19 evaluated on the 14th and
… Our trial enrolled severe COVID-19 patients who were receiving supplemental oxygen or MV…

… -centre, open-label, randomised, controlled trial to investigate cytokine adsorption in adult
patients with severe COVID-19 pneumonia requiring ECMO. Patients with COVID-19 selected …

… In a multi‐center, open‐label, randomized controlled trial of hospitalized adults with
severe COVID‐19, we found no significant differences in the safety or efficacy of standard …

Objective Randomized controlled trials comparing tocilizumab and baricitinib in patients with
coronavirus disease 2019 (COVID-19) are needed. This was an open-label, randomized …

… We report here insights gathered from a single-center open-label phase II randomized
control trial done in Eastern India, on patients with severe COVID-19 disease with evidence for …